|
Market Closed –
|
|
|||
|
490.28 USD |
-19.01% |
490.36 |
+0.02% | |
Published on 05/31/2025 at 08:14
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Regeneron Pharmaceuticals Inc Says Libtayo Shows 68% Reduction In Risk Of Disease Recurrence Or Death |
08:14am |
RE |
|
Healthcare Stocks Rise — Healthcare Roundup |
May. 30 |
DJ |
|
Sector Update: Health Care Stocks Advance Late Afternoon |
May. 30 |
MT |
|
Top Midday Decliners |
May. 30 |
MT |
|
Sector Update: Health Care Stocks Rise in Afternoon Trading |
May. 30 |
MT |
|
Jefferies Lowers Regeneron Pharmaceuticals’ Price Target to $804 From $914 |
May. 30 |
MT |
|
RBC Capital Downgrades Regeneron Pharmaceuticals to Sector Perform From Outperform, Price Target is $662 |
May. 30 |
MT |
|
European Equities Close Mostly Higher in Friday Trading; German Inflation Rises 2.1% in May |
May. 30 |
MT |
|
Wall Street falls as Trump says China violated tariff terms |
May. 30 |
RE |
|
Citigroup Cuts Price Target on Regeneron Pharmaceuticals to $650 From $700 |
May. 30 |
MT |
|
Regeneron shares slide on mixed trial data for smoker’s lung drug |
May. 30 |
RE |
|
Regeneron Facing Headwinds After ‘Underwhelming’ Itepekimab Results, Truist Says |
May. 30 |
MT |
|
Wall St set for lower open as Trump says China violated tariff terms |
May. 30 |
RE |
|
Sector Update: Health Care Stocks Fall Pre-Bell Friday |
May. 30 |
MT |
|
Wells Fargo Downgrades Regeneron Pharmaceuticals to Equal Weight From Overweight, $580 Price Target |
May. 30 |
MT |
|
Tariffs come and go |
May. 30 |
 |
|
Sector Update: Health Care |
May. 30 |
MT |
|
Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Friday Amid US Tariff Reinstatement Decision |
May. 30 |
MT |
|
Wall Street futures down as new court ruling reinstates Trump tariffs |
May. 30 |
RE |
|
Sanofi, Regeneron Pharmaceuticals Report Mixed Results From 2 Phase 3 Trials of Itepekimab |
May. 30 |
MT |
|
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials — Update |
May. 30 |
DJ |
|
Sanofi, Regeneron Pharmaceuticals Report Mixed Results From 2 Phase 3 Trials of Itepekimab |
May. 30 |
MT |
|
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults |
May. 30 |
CI |
|
Sanofi, Regeneron’s Itepekimab Delivers Mixed Results in Late-Stage Trials |
May. 30 |
DJ |
|
Sanofi’s AERIFY-1 Met Primary Endpoint, AERIFY-2 Did Not |
May. 30 |
RE |
REGN: Dynamic Chart
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
– revenues from product sales (53.7%);
– revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%);
– revenues from sales of technology licenses and subcontracted research services (3.6%).
At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.
More about the company
Buy
Last Close Price
490.28USD
Average target price
763.80USD
Spread / Average Target
+55.79%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
